Extracellular TPD expansion Draupnir Bio is advancing oral, small molecule degraders that target extracellular and membrane-bound disease-causing proteins using a lysosome-based approach, presenting a distinct opportunity to partner on programs previously considered undruggable.

Strategic collaborations The company is a spin-out with strong academic lineage and recent funding from Innovation Fund Denmark, Aarhus University, and MP Healthcare, suggesting readiness for co-development or funded partnership models to accelerate upstream discoveries and validation.

Recent validation signals Recent press highlights include Cell Chemical Biology research publications and the launch of the SORTAC platform, signaling market credibility and a clear value proposition for ventures seeking innovative degradation technologies.

Capital and liquidity With total funding around forty-six million dollars and revenue in the low single digits, Draupnir may be seeking strategic exits, license deals, or milestone-rich partnerships to de-risk and monetize its differentiated TPD platform.

Scale-ready capabilities Upside for partners includes access to a platform capable of expanding TPD to extracellular targets, potentially enabling joint programs for high-value, hard-to-drug proteins that align with partnering company portfolios.